ArticleFrontiers in medicine2026
Hemoporfin photodynamic therapy for port-wine stains in children: a prospective study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hemoporfin photodynamic therapy is a promising treatment for port-wine stains. However, its efficacy and safety in pediatric cases remain controversial. This study investigated the efficacy and safety of porphyrin photodynamic therapy for treating port-wine stains in children. Methods: In this prospective study, 140 children with port-wine stains were included and all patients received hemoporfin photodynamic therapy at least twice. Their demographic characteristics, treatment outcomes, and adverse events were recorded. Results: After two treatment sessions, 79.3% of pediatric patients demonstrated a response. The response rate was significantly higher in patients under 6 years old than those aged 12-18 years. The response rate for the red variant of PWS was significantly higher than that for the purple variant. The response rate in the limbs was markedly lower than that in the face. However, gender, prior PDL treatment history, lesion size exceeding 30 cm Conclusion: Hemoporfin photodynamic therapy is an effective and safe treatment for port-wine stains. Patients with the red type, facial involvement, and those under 6 years of age demonstrate superior efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.